Neonatal screening in Spain and cost-effectiveness

作者：Serrano Aguilar Pedro^*; Castilla Rodriguez Ivan; Vallejo Torres Laura; Valcarcel Nazco Cristina; Garcia Perez Lidia

来源：Expert Opinion on Orphan Drugs, 2015, 3(9): 971-974.

DOI：10.1517/21678707.2015.1074072

• cost-effectiveness
• health policy variations
• inborn errors
• newborn screening
• tandem mass spectrometry

Newborn screening (NBS) programs are subject to inter-and intra-country variations, especially after the introduction of tandem mass spectrometry (MS/MS). Access to MS/MS and variations in interpretation of available evidence seem to explain these differences. Cost considerations have had a minor role on funding decisions given the low direct costs to screen an additional disorder by MS/MS and their low frequency. In order to reduce the wide inter-regional observed variations in NBS in Spain, the Ministry of Health supported by the Spanish Network for Health Technology Assessment developed an evidence-based policy decision process guided by a series of effectiveness and cost-effectiveness reports.

• 出版日期2015